Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry

Cancer Science

Volumn 100, Issue 3, 2009, Pages 514-519

  Negishi, Ayako ^a,b   Ono, Masaya ^a   Handa, Yasushi ^c   Kato, Hidenori ^c   Yamashita, Kohki ^c   Honda, Kazufumi ^a   Shitashige, Miki ^a   Satow, Reiko ^a   Sakuma, Tomohiro ^d   Kuwabara, Hideya ^d   Omura, Ken ^b   Hirohashi, Setsuo ^a   Yamada, Tesshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d Mitsui Knowledge Industry Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGED; ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENDOMETRIUM; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; UTERUS CANCER; ENDOMETRIUM TUMOR; METABOLISM; METHODOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

TUMOR MARKER;

ALGORITHMS; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOBLOTTING; MASS SPECTROMETRY; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 62849128405     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01055.x     Document Type: Article

References (31)

1. Kuwabara Y, Susumu N, Banno K et al. Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan. Jpn J Clin Oncol 2005; 35: 23-7.
2. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975; 15: 617-31.
3. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: Results of a prospective study. Br J Cancer 2001; 84: 975-81.
4. Anderson KE, Anderson E, Mink PJ et al. Diabetes and endometrial cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2001; 10: 611-16.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
6. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 2003; 104: 669-76.
7. Rai AJ, Zhang Z, Rosenzweig J et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126: 1518-26.
8. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7.
9. Honda K, Hayashida Y, Umaki T et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 2005; 65: 10613-22.
10. Kakisaka T, Kondo T, Okano T et al. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): Up-regulation of leucine-rich α-2-glycoprotein in pancreatic cancer. J Chromatogr B Anal Technol Biomed Life Sci 2007; 852: 257-67.
11. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422: 198-207.
12. Takahashi N, Kaji H, Yanagida M, Hayano T, Isobe T. Proteomics: Advanced technology for the analysis of cellular function. J Nutr 2003; 133: 2090S-6S.
13. Ishihama Y. Proteomic LC-MS systems using nanoscale liquid chromatography with tandem mass spectrometry. J Chromatogr A 2005; 1067: 73-83.
14. Gao J, Opiteck GJ, Friedrichs MS, Dongre AR, Hefta SA. Changes in the protein expression of yeast as a function of carbon source. J Proteome Res 2003; 2: 643-9.
15. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004; 76: 4193-201.
16. Ishihama Y, Oda Y, Tabata T et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 2005; 4: 1265-72.
17. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 17: 994-9.
18. Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002; 1: 376-86.
19. DeSouza L, Diehl G, Rodrigues MJ et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2005; 4: 377-86.
20. Ono M, Shitashige M, Honda K et al. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006; 5: 1338-47.
21. Kikuchi S, Honda K, Yamada T. Serumalbmin-associated peptides of patients with uterine endometrial cancer. Cancer Sci 2007; 98: 822-9.
22. Idogawa M, Yamada T, Honda K, Sato S, Imai K, Hirohashi S. Poly (ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/β-catenin complex. Gastroenterology 2005; 128: 1919-36.
23. Anderson NL, Anderson NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-67.
24. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096-103.
25. Liu T, Qian WJ, Mottaz HM et al. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006; 5: 2167-74.
26. Kawakami T, Hoshida Y, Kanai F et al. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 2005; 5: 4287-95.
27. Miguet L, Bogumil R, Decloquement P et al. Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. J Proteome Res 2006; 5: 2258-69.
28. States DJ, Omenn GS, Blackwell TW et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006; 24: 333-8.
29. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res 1996; 56: 5309-18.
30. Ehmann M, Felix K, Hartmann D et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007; 34: 205-14.
31. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116: 271-84.